Umbilical cord blood (UCB)-derived CAR-NK cells have been evaluated in a clinical trial of CD19+ malignancies, but only in vitro against CD123 and mesothelin on the surface of AML [84,85,86]. The gene discussed is CD19; the disease is acute myeloid leukemia.